Differences in tumor regulatory T-cell localization and activation status impact patient outcome.
The presence of regulatory T cells (Treg) has been described in a large panel of solid tumors. However, their impact on tumor progression differs according to the tumor type analyzed. We recently obtained evidence in breast carcinoma that Treg localized within lymphoid aggregates, but not in the tumor bed, have a negative impact on patients' survival. Moreover, we showed selective Treg recruitment through CCR4/CCL22 in the lymphoid aggregates upon contact with dendritic cells (DC), where they became strongly and selectively activated (ICOS(high)) and block conventional T-cell response. Here, we discuss the meaning and potential implication of these novel findings.
Ménétrier-Caux
Christine
C
Inserm, U590, Centre Léon Bérard, Equipe Cytokines et Cancers, Université Lyon 1, ISPB, and IFR62, Lyon, France. caux@lyon.fnclcc.fr.
Gobert
Michael
M
Caux
Christophe
C
D006801:Humans; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000473:pathology